Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab.
read more
Source: NY Times
15:29, July 20, 2021
Pam Belluck, Sheila Kaplan and Rebecca Robbins
Why the Markets Worry About the Delta Variant
14:26, July 20, 2021
Andrew Ross Sorkin, Jason Karaian, Sarah Kessler, Stephen Gandel, Michael J. de la Merced, Lauren Hirsch and Ephrat Livni